Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
2019 ◽
Vol 20
(10)
◽
pp. 1444-1453
◽
Keyword(s):
Phase 3
◽